益比奥大剂量冲击维持疗法对恶性肿瘤贫血的疗效探讨

Clinical effect of therapy with high-dose recombinant human erythropoietin on cancer-related anemia

目的:比较益比奥大剂量冲击维持疗法和常规剂量法对恶性肿瘤贫血的疗效。方法:将恶性肿瘤贫血患者随机分为对照组(益比奥40000U,每周1次,共7次)与试验组(益比奥40000U,第1、4、7、10、13、20、27、34、41天),共观察8周,每2周进行1次评价疗效。结果:试验组治疗2周后血红蛋白明显升高,对照组4周后血红蛋白明显升高;试验组的4、6、8周血红蛋白值均高于对照组(P<0.05);试验组的2、4、6、8周有效率分别为41.9%、64.5%、83.9%、87.1%,高于对照组的16.1%、32.3%、54.8%、61.3%(P<0.05);在提高患者生活质量方面,试验组也优于对照组(P<0.05)。两组输血需求率及不良反应发生率无明显差异(P>0.05)。结论:益比奥大剂量冲击维持疗法对恶性肿瘤贫血的疗效优于常规剂量法。

Objective：To compare the clinical effect of common -dose recombinant human erythropoietin（rhEPO） with high - dose rhEPO on anemia with malignancies. Methods：Anemic patients with malignancies were divided randomly into the control group（ rhEPO 40 000U administered weekly for 7 times） and the experiment group（rhEPO 40 000 U administered in days 1,4,7,10,13,20,27,34,41 ）. Clinical observations were performed every 2 weeks. Re- sults：Hemoglobin level of the experiment group increased significantly after 2 weeks, while that of the control group increased significantly after 4 weeks, the former was higher than the latter after 4,6,8 weeks. The effect rates of 2,4, 6,8 weeks were 41.9% ,64.5% , 83.9% and 87.1% respectively in the experiment group, higher than 16.1% , 32.3% ,54.8% and 61.3% in the control group（P 〈0.05）. The experiment group was better than the control group in improving patientsqualities of life. There were no statistical differences in side effects and transfusion rates between the two groups（P 〉 0.05）. Conclusion：The effect of rhEPO with high dose was better than rh EPO with common - dose on anemic patients with malignancies.